Heart Failure with preserved Ejection Fraction (HFpEF), like other heart failure syndromes, is heterogeneous in etiology and pathophysiology, rather than a single disease. HFpEF may account for about half of all patients with heart failure. Patients have symptoms and signs of HF with normal or near normal left ventricular EF (LV EF>50 %). The classical risk factors for developing HFpEF include advanced age and co-morbidities, notably hypertension, atrial fibrillation, and the metabolic syndrome. When complicated by increasing congestion requiring hospital admission, the prognosis is poor; 30% or more of such patients will die within 1 year (nearly two-thirds die from cardiovascular causes). Patients with chronic stable symptoms have a better prognosis. Patients with HFpEF represent an important group of patients presenting in clinical practice with HF. Overall, it appears that patients with HFpEF are at lower risk of death than patients with HFrEF, although mortality remains high in both groups. Application of the same therapeutic hypotheses that have been successfully utilized among patients with HFrEF have not been demonstrated to result in improved survival.
The syndrome of HFpEF has shown, on virtually every front, consensus-based diagnostic criteria resulting in a heterogeneous population challenging for clinical studies and trials. Moreover, the prevalence, morbidity, mortality, and healthcare costs of HFpEF is rising, in a similar way as HF with reduced EF (HFrEF). The aging population and increased life expectancy have led to the rising prevalence of heart failure (HF) and despite the improvements in medical therapy, the mortality rate of this condition has remained unacceptably high. [2] The diagnosis is generally made by history, physical examination and echocardiography (with the possible addition of tests such as plasma natriuretic peptide level or cardiopulmonary exercise testing). The management of HFrEF has improved significantly over the last two decades by contrast, little or no progress has been made in identifying evidence-based, effective treatments for HFpEF. Large phase III international clinical trials investigating interventions to improve outcomes in HFpEF have yielded disappointing results. [3] Irrespective of specific diagnostic criteria and cut-offs, HFpEF is a syndrome where multiple cardiac and vascular abnormalities, cardiovascular risk factors, and overlapping extra-cardiac comorbidities may be present in various combinations as shown in (Table 1) .
Pathophysiological abnormalities.
Clinical syndromes Ventricular Dysfunction: -impaired relaxation -impaired filling -Systolic dysfunction
COPD

Atrial Dysfunction
Iron Deficiency Anemia Autonomic Dysfunction Chronotropic incompetence
Renal dysfunction with fluid volume overload
Vascular Dysfunction Vascular stiffening Ventriculo-arterial coupling
Aging and deconditioning
Elevated Blood -inadquate BP response and Pulmonary hypertension
Obesity and Sarcopenia
Dynamic mitral valve regurgitation
Psychiatric disorders (depression)
Hypertension, Diabetes, ROS production Table ( 1) Heterogeneity of the heart failure with preserved ejection fraction syndrome. BP = blood pressure; COPD = chronic obstructive pulmonary disease.
Matching treatment strategies to a specific patient's phenotype in HFpEF is a promising approach that warrants testing in clinical trials and may increase the likelihood of demonstrating clinical benefit (Table 2) . Targeting specific phenotypes instead of following the 'one-size-fits-all' approach becomes increasingly important in the light of several failed, non-targeted, large-scale HFpEF trials. [4] In a recent review of 25 RCTs comprising data for 18101 patients. All-cause mortality was reduced with beta-blocker therapy compared with placebo (RR: 0.78, 95%CI 0.65 to 0.94, p=0.008). There was no effect seen with ACE inhibitors, aldosterone receptor blockers, mineralocorticoid receptor antagonists and other drug classes, compared with placebo. Similar results were observed for cardiovascular mortality. No single drug class reduced heart failure hospitalization compared with placebo. [5] A Mayo Clinic study examined all consecutive patients hospitalized with decompensated HF from 1987 through 2001.The proportion of patients with the diagnosis of HFpEF increased over time and was significantly higher among community patients than among referral patients (55 versus 45 percent). Over the next decade (2000 through 2010), the proportion of HF patients with HFpEF continued to increase while the incidence of HFpEF and HFrEF declined. Diastolic function worsens as part of aging even in individuals without other forms of cardiovascular disease, asymptomatic diastolic dysfunction is a predictor of future cardiovascular morbidity, but prognosis differs from that in patients with symptoms of HFpEF. [7] Asymptomatic diastolic dysfunctionDiastolic dysfunction with normal systolic function without HF (also known as preclinical diastolic dysfunction) is a common finding in older adults and a predictor of mortality, as illustrated by the following studies:
In the Mayo Clinic cross-sectional community survey of 2042 adults ≥45 years of age, 21 percent had mild diastolic dysfunction, 7 percent had moderate which patient data were not available, the weighted mean from published data showed that these patients were slightly older (mean age 71 years), fewer were women (34%), and the proportion of patients with missing EF was higher (33%) than the included studies.
Figure 3: Flow Chart; The meta-analysis of the MAGGIC studies
The conclusion of this meta-analysis showed that patients with HFpEF have a lower risk of death than patients with HFrEF, and this difference is seen regardless of age, gender, and aetiology of HF. However, absolute mortality is still high in patients with HFpEF highlighting the need for a treatment to improve prognosis.
Symptomatic patients with HFpEF)
The prognosis of patients with HFpEF (ie, symptomatic HF) is less well defined than that of patients with HFrEF. Populationbased data from hospitalized patients have shown similar outcomes in patients with HFpEF and HFrEF. However, a large metaanalysis, including community-based studies and trials, observed lower mortality in HFpEF compared with HFrEF, though survival was still much worse than in people without HF. Among patients hospitalized for HF, the mortality rates are higher but the data are again conflicting as to whether or not the prognosis is different in HFpEF and HFrEF: [12] Among 6076 patients discharged from a Mayo Clinic Hospital in Olmsted County, Minnesota with a diagnosis of decompensated HF over a 15-year period (1987 to 2001), 53 percent had a reduced LVEF and 47 percent had a preserved LVEF. One-year mortality was relatively high in both groups but slightly lower in patients with a preserved LVEF (29 versus 32 percent in patients with reduced LVEF, adjusted hazard ratio 0.96, 95% CI 0.92-1.00). Survival improved over time for those with reduced LVEF but not for those with preserved LVEF. [13] In a cohort of 2802 patients discharged from 103 hospitals in Ontario with a diagnosis of decompensated HF, one-year mortality was 22 percent in patients with a preserved LVEF versus 26 percent in patients with a reduced LVEF. This difference was not statistically significant. [14] HFpEF in patients with acute myocardial infarction.
In a study of 1,474 patients with acute myocardial infarction, One-third of patients admitted with heart failure had preserved left ventricular ejection fraction. Although this subgroup exhibited more favorable outcomes than those with systolic dysfunction, this condition presented a three-fold higher risk of death than the group without heart failure. Patients with acute myocardial infarction and heart failure with preserved left ventricular ejection fraction encounter elevated short-term risk and require special attention and monitoring during hospitalization. [15] Independent predictors of mortality in patients with HFpEF in different studies include older age, male gender, New York Heart Association (NYHA) class, lower LVEF, the extent of coronary artery disease, peripheral artery disease, diabetes, impaired renal function, the degree of diastolic dysfunction as assessed by Doppler echocardiography, and increased red cell distribution width Morbidity outcomes in HFrEF and HFpEF are similar. These include the rate and frequency of hospitalization for HF, symptomatic status as measured by abnormalities in myocardial oxygen consumption, six-minute walk distance, Minnesota Living with Heart Failure questionnaire scores, and other quality-oflife indicators. Therefore, patients with HFpEF have a morbidity burden equivalent to that in patients with HFrEF. Diastolic HF is associated with high mortality comparable with that of HF with depressed ejection fraction with a five year survival rate after a first episode of 43% and a higher excess mortality compared with the general population.
In patients with diastolic HF older age, male gender, non-Caucasian ethnicity, history of coronary artery disease and atrial fibrillation are associated with poor prognosis. Anemia and B-type natriuretic peptide are significant laboratory variable that predict mortality. Two dimensional echocardiography and tissue Doppler imaging measurements including left ventricular ejection fraction, E/Ea ratio ≥ 15, restrictive transmiral filling (deceleration time £ 140 ms) and Em < 3.5 cm/s(early diastolic mitral annulus velocity) are predictors of adverse outcomes in diastolic HF patients. However, In a retrospective study of 289 patients (Age group 79 ± 7) which investigated 5-year-mortality and its prognostic factors in old patients with HFpEF compared with those with HFrEF it was found that HFpEF has a better longterm prognosis than HFrEF and a distinct prognostic risk profile. Morbidity outcomes in HFrEF and HFpEF are similar .These include the rate and frequency of hospitalization for HF, symptomatic status as measured by abnormalities in myocardial oxygen consumption, six-minute walk distance, Minnesota Living with Heart Failure questionnaire scores, and other quality-of-life indicators. Therefore, patients with HFpEF have a morbidity burden equivalent to that in patients with HFrEF [16] . Among patients hospitalized with HF, patients with HFpEF with borderline EF had lower mortality and higher all-cause readmission risk than patients with HFrEF, although the mortality differences did not persist after risk adjustment. Irrespective of EF [17] .
Conclusion
Although there has been considerable progress in the management of systolic heart failure (SHF), the management of HFpEF remains mostly empirical because of lack of knowledge of the molecular and biochemical mechanisms which produce myocardial structural and functional changes in this syndrome. There is a lack of consensus on the basic pathophysiology, definition, and therapeutic targets for therapy for this syndrome. The syndrome of heart failure with preserved ejection fraction (HFpEF) remains poorly understood and portrays a significant burden in terms of prevalence, morbidity, mortality, and health care costs. The proportions of cardiovascular and non-cardiovascular deaths among patients with HFpEF have varied among trials and epidemiologic studies, with higher proportions of non-cardiovascular deaths in population-based studies. Morbidity in HFpEF is similar to that in HFrEF.
